Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Common Equity (2022 - 2025)

BioXcel Therapeutics has reported Common Equity over the past 4 years, most recently at -$95.5 million for Q4 2025.

  • Quarterly results put Common Equity at -$95.5 million for Q4 2025, down 2.54% from a year ago — trailing twelve months through Dec 2025 was -$95.5 million (down 2.54% YoY), and the annual figure for FY2025 was -$95.5 million, down 2.54%.
  • Common Equity for Q4 2025 was -$95.5 million at BioXcel Therapeutics, down from -$88.9 million in the prior quarter.
  • Over the last five years, Common Equity for BTAI hit a ceiling of $194.0 million in Q1 2022 and a floor of -$107.7 million in Q2 2025.
  • Median Common Equity over the past 4 years was -$64.4 million (2023), compared with a mean of -$11.5 million.
  • Biggest five-year swings in Common Equity: plummeted 1367.07% in 2024 and later fell 2.54% in 2025.
  • BioXcel Therapeutics' Common Equity stood at $76.8 million in 2022, then tumbled by 173.6% to -$56.5 million in 2023, then crashed by 64.76% to -$93.1 million in 2024, then dropped by 2.54% to -$95.5 million in 2025.
  • The last three reported values for Common Equity were -$95.5 million (Q4 2025), -$88.9 million (Q3 2025), and -$107.7 million (Q2 2025) per Business Quant data.